New hope for Alzheimer's patients: Medicines slow progress by 30%!

New hope for Alzheimer's patients: Medicines slow progress by 30%!

Austria Center Vienna, Wien, Österreich - On March 25, 2025, studies report significant progress in Alzheimer's therapy. Two new drugs, Lecanemab and Donanemab, have the potential to slow down the clinical progression of the disease in the early stage by up to 30 %, according to Nature.com . Of these, 18 studies comprised more than 21,000 participants and were interpreted as placebo-controlled, double-faded studies.

• Bapineuzumab: 4 studies
• Solanezumab: 4 studies
• gantenerumab: 3 studies
• Crenezumab: 2 studies
• aducanumab: 2 studies
• Donanemab: 1 study
• Lecanemab: 1 study

Despite the significant reduction in amyloid deposits by these medication, it was shown that the clinical effects were small and often below the relevant threshold values. Kidney studies were demolished prematurely and the risk reviews showed that the majority of studies worked with low risk.

research on beta-amyloid deposits

Additional insights into therapy development provides the project to research the first beta-amyloid deposits in the brain, which is led by the German Center for Neurodegenerative Diseases (DZNE). Under the direction of Dr. Alejandro Iván Ruiz Riquelme examines the project The biology of beta-amyloid aggregates and its role in Alzheimer's disease. The aim is to develop therapies against Alzheimer's before the first symptoms occur and to develop antibodies to combat these deposits, as on alzheimer-forschung described.